The anti‐CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6‐month, open‐label Phase I clinical trial

Itolizumab is a humanized anti‐CD6 monoclonal antibody (mAb) that has previously shown encouraging results, in terms of safety and positive clinical effects, in a 6‐week monotherapy clinical trial conducted in rheumatoid arthritis (RA) patients. The current Phase I study evaluated the safety and cli...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clin Exp Immunol
Hauptverfasser: Rodríguez, P. C., Prada, D. M., Moreno, E., Aira, L. E., Molinero, C., López, A. M., Gómez, J. A., Hernández, I. M., Martínez, J. P., Reyes, Y., Milera, J. M., Hernández, M. V., Torres, R., Avila, Y., Barrese, Y., Viada, C., Montero, E., Hernández, P.
Format: Artigo
Sprache:Inglês
Veröffentlicht: John Wiley and Sons Inc. 2017
Schlagworte:
Original Articles
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5758380/
https://ncbi.nlm.nih.gov/pubmed/28963724
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.13061
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge